WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the appointment of three clinical advisors and new ...

Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly ...

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported ...

Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in a Phase 2 clinical ...

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

Thank you for standing by, and welcome to the Upstream Bio Phase II VIBRANT Top-line Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to ...

- Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use- -Secondary endpoints also provided strong ...

Upstream Bio (UPB) is scheduled to report Q2 earnings on August 5, 2026. Analysts estimate EPS of $-0.76 and quarterly revenue of $503.74K. In the most recent quarter (Q1), Upstream Bio reported EPS ...

- Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP - - Company ...